Medilink TherapeuticsGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
Tag Archive for: cancer
Adaütimmune LtdThe US Food & Drug Administration has granted accelerated approval to Adaptimmune’s Tecelra as the world’s first therapy with genetically engineered T cells to fight a solid tumour.
SIATWith an investment of its venture arm (BI-VF), Boehringer Ingelheim underlines its committment to expand the reach of cancer immune therapies. The Series A financing in Chinese Synthetica Pioneering that engineers oncolytic bacteria to deliver toxic payloads or modulators of the tumour environment to solid tumours follows an investment in T3 Pharmaceuticals.
ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11.
Swiss antibody specialist Memo Therapeutics AG has added CHF20m to its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
Flagging of CAR-T cells with the B7H6 protein weakened the response to human leukaemia in models as it marks them for NK cell attack, German researchers report.
Paris-based Klineo SAS has raised €2M to speed up access to clinical trials for oncology patients using an AI platform.
`
Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.
British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.